BioSpace News Archive

Nevro Corp. announced that the company will report its financial results for the third quarter ended September 30, 2022 after the market closes on November 2, 2022.

Molecular Testing Labs, a mission-driven, innovative health sciences company specializing in clinical diagnostics, announced they have selected Jason Hall as their Chief Financial Officer.

Asahi Kasei, a diversified Japanese multinational company, and subsidiary Crystal IS have concluded in a bacterial performance test that an experimental Klaran™ WR water treatment reactor demonstrated over 75% higher performance than a traditional low pressure mercury lamp system using an equivalent power consumption level.

HAPPE Spine announces the addition of two more issued patents in a growing portfolio establishing HAPPE as the leader of next generation orthopaedic and spinal implants enabled by the HAPPE™ platform.

Lyell Immunopharma, Inc. announced that five abstracts highlighting preclinical data on its product candidates and new genetic and epigenetic reprogramming technologies were accepted for presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer taking place in Boston, Nov. 8 – Nov. 12, 2022.

Fate Therapeutics, Inc. announced that the Company will present clinical and preclinical data for the Company’s induced pluripotent stem cell product platform at the Society for Immunotherapy of Cancer 37th Annual Meeting being held in Boston, MA, and virtually, November 8-12, 2022.

Agenus Inc. announced the Company will present new data on its growing portfolio of clinical-stage immuno-oncology programs at the Society for Immunotherapy of Cancer 37th Annual Meeting, to be held November 8-12 in Boston, MA and virtually.

PDS Biotechnology Corporation announced that two abstracts reporting the results of clinical development studies of PDS0101 have been accepted for presentation at the 37th Annual Meeting for the Society for Immunotherapy of Cancer being held November 8-12, 2022, in Boston.

Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and Greg Cosgrove, M.D., FCCP, Vice President, Clinical Development, will present a corporate overview at the Pulmonary/Lung Disease Mini-Symposium, a part of RBC’s Biotech Expert Insights Series.

Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James Securities 2022 Small Cap Growth Conference on Wednesday, October 12, 2022 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time).